Loading…
Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.
Israeli medical device company developing Alpha DaRT, a radiation therapy using alpha particles to treat solid tumors.
No widely sold product yet, so it is funded by cash raised from investors and spends it on clinical trials and on building up production of its radioactive sources. Regulatory approvals in each country decide when sales can begin. It went public through a 2022 merger with a blank-cheque company.
In one line: An early-stage alpha-radiation cancer therapy company.
Moat: narrow (IP / patents). Patented alpha-particle radiation technology offers a novel localized cancer treatment approach.
Headquarters: Jerusalem, Israel · Founded: 2016 · Employees: 112
Size Alpha Tau Medical (DRTS) is a United States Health Care company (Medical Specialties) with a market value of $1.27B, the 2102nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.72 on 6 Nov 2026.
Performance Over six months the shares gained 61.2%, against -6.7% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Valuation It trades at 28.76× book value against a peer median of 3.29× (3rd most expensive of 21).
Price implies The share price implies a return on equity of about 241.4%; Alpha Tau Medical delivers -141.7%, so the price asks more than the business earns today.
Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | -$1.23M | -$1.10M | -$1.07M | -$979,000 |
| EBITDA | n/a | -$41.1M | -$34.9M | -$34.6M | -$31.2M |
| Net income | -$92.6M | -$42.6M | -$31.8M | -$29.2M | -$33.8M |
| Free cash flow | n/a | -$32.8M | -$22.0M | -$24.4M | -$24.8M |
| Capital expenditure | n/a | $6.08M | $2.24M | $6.40M | $904,000 |
| Total debt | $15.2M | $13.7M | $12.5M | $13.3M | $5.19M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Alpha Tau Medical DRTS | $1.27B | +61% | n/a | -142% | 28.76× | 241.4% |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 12% | 2.62× | 16.6% |
| Elekta EKTA-B.ST | $2.37B | +8% | -7% | -4% | 3.07× | 20.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DRTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | +1.7% | 9th lowest of 21 |
| 6-month return | +61.2% | -6.7% | highest of 21 |
| Return on equity | -141.7% | 5.7% | 2nd lowest of 21 |
| Price / book | 28.76× | 3.29× | 3rd most expensive of 21 |
| ROE the price implies | 241.4% | 23.1% | most demanding of 20 |
| ROE delivered | -141.7% | 5.7% | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | -142% | 28.76× | 241.4% | -141.7% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 8% | 2.84× | 18.1% | 8.4% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 1% | 3.46× | 30.6% | 1.1% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -27% | 30.51× | 236.5% | -27.4% |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 26% | 3.07× | 12.0% | 26.3% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 6% | 1.96× | 14.5% | 5.8% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | -1% | 3.85× | 22.0% | -1.1% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 2% | 1.29× | 7.6% | 1.6% |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -30% | 3.47× | 24.6% | -30.2% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -48% | 9.02× | 91.9% | -48.0% |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 8% | 7.21× | 95.2% | 7.8% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -308% | 89.96× | n/a | -308.1% |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 12% | 4.12× | 24.9% | 12.4% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 6% | 3.13× | 8.1% | 5.7% |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 2% | 1.84× | 12.8% | 1.9% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 10% | 1.84× | 23.1% | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 7% | 2.07× | 13.1% | 6.6% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 14% | 3.05× | 29.3% | 14.1% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 14% | 6.66× | 48.4% | 14.3% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -8% | 1.72× | 11.9% | -7.7% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 23% | 10.37× | 69.6% | 23.4% |